46 related articles for article (PubMed ID: 36740988)
1. Lactate receptor GPR81 drives breast cancer growth and invasiveness through regulation of ECM properties and Notch ligand DLL4.
Lundø K; Dmytriyeva O; Spøhr L; Goncalves-Alves E; Yao J; Blasco LP; Trauelsen M; Ponniah M; Severin M; Sandelin A; Kveiborg M; Schwartz TW; Pedersen SF
BMC Cancer; 2023 Nov; 23(1):1136. PubMed ID: 37993804
[TBL] [Abstract][Full Text] [Related]
2. Notch3 restricts metastasis of breast cancers through regulation of the JAK/STAT5A signaling pathway.
Chen MN; Fang ZX; Wu Z; Bai JW; Li RH; Wen XF; Zhang GJ; Liu J
BMC Cancer; 2023 Dec; 23(1):1257. PubMed ID: 38124049
[TBL] [Abstract][Full Text] [Related]
3. DLL4/Notch3/WNT5B axis mediates bidirectional prometastatic crosstalk between melanoma and lymphatic endothelial cells.
Alve S; Gramolelli S; Jukonen J; Juteau S; Pink A; Manninen AA; Hänninen S; Monto E; Lackman MH; Carpén O; Saharinen P; Karaman S; Vaahtomeri K; Ojala PM
JCI Insight; 2024 Jan; 9(1):. PubMed ID: 37971882
[TBL] [Abstract][Full Text] [Related]
4. Role of Notch signaling pathway in gastric cancer: a meta-analysis of the literature.
Du X; Cheng Z; Wang YH; Guo ZH; Zhang SQ; Hu JK; Zhou ZG
World J Gastroenterol; 2014 Jul; 20(27):9191-9. PubMed ID: 25083094
[TBL] [Abstract][Full Text] [Related]
5. The Role of
Aburjania Z; Jang S; Whitt J; Jaskula-Stzul R; Chen H; Rose JB
Oncologist; 2018 Aug; 23(8):900-911. PubMed ID: 29622701
[TBL] [Abstract][Full Text] [Related]
6. Expressions and Prognostic Values of Notch3 and DLL4 in Human Breast Cancer.
Wang L; Cao G; Li W; Chen XW; Xiong SS; Mu YN; Jiang JF; Yang L; Zhang DR; Cao YW
Technol Cancer Res Treat; 2023; 22():15330338221118984. PubMed ID: 36740988
[No Abstract] [Full Text] [Related]
7. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
8. Highly Expressed DLL4 and JAG1: Their Role in Incidence of Breast Cancer Metastasis.
Zohny SF; Zamzami MA; Al-Malki AL; Trabulsi NH
Arch Med Res; 2020 Feb; 51(2):145-152. PubMed ID: 32111499
[TBL] [Abstract][Full Text] [Related]
9. Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells.
Rajabi A; Saber A; Pourmahdi M; Emami A; Ravanbakhsh R; Khodavirdipour A; Khodaei M; Akbarzadeh M; Abdolahi S; Hosseinpourfeizi MA; Safaralizadeh R
Recent Pat Anticancer Drug Discov; 2020; 15(4):329-340. PubMed ID: 32990541
[TBL] [Abstract][Full Text] [Related]
10. Delta-like ligand 4 level in colorectal cancer is associated with tumor aggressiveness and clinical outcome.
Zhang Z; Li X; Yan X; Qiu H; Li G; Guo X; Lu Y; Yang J; Jiao M; Chen X; Zhu S; Dang C; Wang W; Chu D
Cancer Biomark; 2022; 33(3):415-422. PubMed ID: 34487019
[TBL] [Abstract][Full Text] [Related]
11. DLL1- and DLL4-Mediated Notch Signaling Is Essential for Adult Pancreatic Islet Homeostasis.
Rubey M; Chhabra NF; Gradinger D; Sanz-Moreno A; Lickert H; Przemeck GKH; Hrabě de Angelis M
Diabetes; 2020 May; 69(5):915-926. PubMed ID: 32029480
[TBL] [Abstract][Full Text] [Related]
12. KCNQ1OT1 affects cell proliferation, invasion, and migration through a miR-34a / Notch3 axis in breast cancer.
Ren Z; Xu Y; Wang X; Ren M
Environ Sci Pollut Res Int; 2022 Apr; 29(19):28480-28494. PubMed ID: 34993814
[TBL] [Abstract][Full Text] [Related]
13. The Role of Notch3 Signaling in Cancer Stemness and Chemoresistance: Molecular Mechanisms and Targeting Strategies.
Xiu M; Wang Y; Li B; Wang X; Xiao F; Chen S; Zhang L; Zhou B; Hua F
Front Mol Biosci; 2021; 8():694141. PubMed ID: 34195229
[TBL] [Abstract][Full Text] [Related]
14. The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance.
Nandi A; Chakrabarti R
Genes Dev; 2020 Nov; 34(21-22):1422-1438. PubMed ID: 33872192
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
